Spoken Alpha
Cue Biopharma, Inc.
Cue Biopharma develops injectable immunotherapies using its Immuno-STAT platform to selectively engage and modulate disease-specific T cells for treating autoimmune, inflammatory, and oncology indications.
Cue Biopharma, Inc is a Healthcare company operating in Biotechnology with a $240.8M market cap.
CUE missed consensus EPS by 1.0% in Q2 FY2026, reported Aug 13, 2026.
9 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CUE.
$ curl https://api.spokenalpha.com/v1/companies/CUEFAQ
Spoken Alpha indexes CUE's earnings call transcripts at https://spokenalpha.com/companies/CUE. Each call links to attributed speakers and parsed analyst Q&A.
Cue Biopharma, Inc. (CUE) held its most recent earnings call on 2024-08-19, covering fiscal Q2 2024.
Cue Biopharma, Inc. (CUE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-13 | $-13.81 | $-1.69 | -100.0% | $7.9M | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-1.08 | $-3.30 | +67.3% | $5.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $0.01 | $-0.09 | +100.0% | $21.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-2.10 | $-2.55 | +17.6% | $2.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.70 | $-3.90 | +30.8% | $3.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-5.10 | $-4.60 | -10.9% | $421.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.13 | $-0.14 | +11.7% | $1.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-5.13 | $-5.70 | +10.0% | $3.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-6.00 | $-8.40 | +28.6% | $2.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-7.50 | $-8.78 | +14.6% | $1.7M | — | — | EODHD |
| Q4 FY2023 | 2024-03-27 | $-0.29 | $-0.28 | -3.6% | $1.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-02 | $-7.20 | $-10.28 | +30.0% | $2.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-8.70 | $-9.15 | +4.9% | $1.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-8.70 | $-8.70 | 0.0% | $187.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-20 | $-0.38 | $-0.31 | -22.6% | $151.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-9.30 | $-11.40 | +18.4% | $68.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-11.10 | $-12.00 | +7.5% | $26.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-13.20 | $-12.60 | -4.8% | $1.0M | — | — | EODHD |
| Q4 FY2021 | 2022-03-15 | $-0.25 | $-0.38 | +34.2% | $8.3M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-12.30 | $-11.10 | -10.8% | $2.4M | — | — | EODHD |
Source: EODHD. CUE reported actuals as published; sparse fields render as —.